|07/26/17||Pacira Announces Publication of Phase 4 Study of EXPAREL in Patients Undergoing Total Knee Replacement in The Journal of Arthroplasty|
|PILLAR study demonstrated a 78 percent decrease in opioid consumption and significantly better pain control with infiltration of EXPAREL plus bupivacaine versus bupivacaine alone
Ten percent of patients in the EXPAREL arm required no opioids for pain control
PARSIPPANY, N.J., July 26, 2017 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced the publication of its Phase 4 PILLAR study of EXPAREL® (bupivacaine liposome injectable suspension) in total knee arthroplast... |
|07/25/17||Pacira Pharmaceuticals Announces Timing for Second Quarter 2017 Financial Results Webcast and Conference Call|
|PARSIPPANY, N.J., July 25, 2017 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that it will report its second quarter financial results before the open of the U.S. markets on Wednesday, August 2, 2017. The announcement will be followed by a conference call at 8:30 a.m. ET. Participating in the call from Pacira will be Dave Stack, chairman and chief executive officer, and other members of the company’s senior management team.
The call can be accessed by dialin... |
|07/25/17||Pacira Announces Topline Phase 3 Results for EXPAREL® as a Single-dose Nerve Block|
|Upper extremity study showed that EXPAREL significantly reduces pain scores and opioid use
Lower extremity study defined safety and pharmacokinetic profile through 120 hours
Timing for resubmission of supplemental New Drug Application remains on track
Conference call scheduled for today at 8:30 AM ET
PARSIPPANY, N.J., July 25, 2017 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced the completion of two Phase 3 placebo-controlled studies evaluating the effica... |
|06/15/17||Pacira Pharmaceuticals Appoints Mark I. Froimson, M.D., to Board of Directors|
|PARSIPPANY, N.J., June 15, 2017 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced the appointment of Mark I. Froimson, M.D. to its board of directors. Dr. Froimson is currently serving as the President of the American Association of Hip and Knee Surgeons (AAHKS). Previously, he was the Executive Vice President and Chief Clinical Officer of Trinity Health, a major national non-profit Catholic healthcare system comprising 93 hospitals in 22 states.
“Mark’s deep cl... |